Sign In
Buy CLPT
$13.30
+0.93 (+7.52%)
At Close: Jun 03, 2026
Top 5 Health Care Stocks That Are Set To Fly In Q2 - ClearPoint Neuro (NASDAQ:CLPT), Belite Bio (NASDAQ:BLTE)
08:40am, Friday, 09'th Jun 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ClearPoint Neuro: I Continue To Rate The Stock A 'Buy'
05:02am, Monday, 05'th Jun 2023
ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The com
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs
03:45pm, Wednesday, 31'st May 2023
When looking for big winners in the stock market, smaller is better. A gigantic firm like Apple (NASDAQ: AAPL ) can realistically only go up so much in a given time period.
ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
04:01pm, Thursday, 18'th May 2023
SOLANA BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the br
ClearPoint Neuro, Inc. (CLPT) Q1 2023 Earnings Call Transcript
08:05pm, Thursday, 11'th May 2023
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkin
SOLANA BEACH, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the br
ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
04:42pm, Friday, 28'th Apr 2023
SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the
3 Healthcare Stocks With Huge Growth Potential
06:21pm, Monday, 24'th Apr 2023
It's been a rocky market for growth stocks over the past 18 months. We've seen a flurry of layoffs and spending cutbacks from leading tech companies.
ClearPoint Neuro, Inc. (CLPT) Q4 2022 Earnings Call Transcript
07:25pm, Wednesday, 01'st Mar 2023
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takk
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023
04:05pm, Wednesday, 15'th Feb 2023
SOLANA BEACH, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the b
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash Burn
01:30am, Monday, 30'th Jan 2023
ClearPoint Neuro is a growth story and should be evaluated as such. I break down some of the growth factors that I consider most important.
ClearPoint Neuro to Present at Upcoming Investor Conferences
09:25am, Wednesday, 09'th Nov 2022
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the b
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
08:18pm, Tuesday, 08'th Nov 2022
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
ClearPoint Neuro, Inc. (CLPT) Q3 2022 Earnings Call Transcript
06:15pm, Tuesday, 08'th Nov 2022
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants William
ClearPoint Neuro: Continuous Great Execution
12:56pm, Monday, 19'th Sep 2022
Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly
